Positron Emission Tomography-Computed Tomography (PET-CT) Versus No PET-CT in the Management of Potentially Resectable Colorectal Cancer Liver Metastases: Cost Implications of a Randomized Controlled Trial [BUSINESS OF ONCOLOGY]

Conclusion:
PET-CT was associated with limited clinical benefit and a nonsignificant increased cost. Universal funding of PET-CT in the management of patients with resectable colorectal cancer liver metastases does not seem justified.

Source: Journal of Oncology Practice - July 11, 2016 Category: Cancer & Oncology Authors: Serrano, P. E., Gafni, A., Gu, C.-S., Gulenchyn, K. Y., Julian, J. A., Law, C., Hendler, A. L., Moulton, C.-A., Gallinger, S., Levine, M. N. Tags: Imaging, Epidemiology, Diagnosis & Staging, Surgery, Chemotherapy, Diagnosis & Staging, Surgery, Nuclear Medicine and PET, CT BUSINESS OF ONCOLOGY Source Type: research